Cargando…

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Biryukov, Sergei S., Wu, Hua, Dankmeyer, Jennifer L., Rill, Nathaniel O., Klimko, Christopher P., Egland, Kristi A., Shoe, Jennifer L., Hunter, Melissa, Fetterer, David P., Qiu, Ju, Davies, Michael L., Bausch, Christoph L., Sullivan, Eddie J., Luke, Thomas, Cote, Christopher K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204441/
https://www.ncbi.nlm.nih.gov/pubmed/37218899
http://dx.doi.org/10.3390/antib12020033
_version_ 1785045834644062208
author Biryukov, Sergei S.
Wu, Hua
Dankmeyer, Jennifer L.
Rill, Nathaniel O.
Klimko, Christopher P.
Egland, Kristi A.
Shoe, Jennifer L.
Hunter, Melissa
Fetterer, David P.
Qiu, Ju
Davies, Michael L.
Bausch, Christoph L.
Sullivan, Eddie J.
Luke, Thomas
Cote, Christopher K.
author_facet Biryukov, Sergei S.
Wu, Hua
Dankmeyer, Jennifer L.
Rill, Nathaniel O.
Klimko, Christopher P.
Egland, Kristi A.
Shoe, Jennifer L.
Hunter, Melissa
Fetterer, David P.
Qiu, Ju
Davies, Michael L.
Bausch, Christoph L.
Sullivan, Eddie J.
Luke, Thomas
Cote, Christopher K.
author_sort Biryukov, Sergei S.
collection PubMed
description Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.
format Online
Article
Text
id pubmed-10204441
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102044412023-05-24 Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague Biryukov, Sergei S. Wu, Hua Dankmeyer, Jennifer L. Rill, Nathaniel O. Klimko, Christopher P. Egland, Kristi A. Shoe, Jennifer L. Hunter, Melissa Fetterer, David P. Qiu, Ju Davies, Michael L. Bausch, Christoph L. Sullivan, Eddie J. Luke, Thomas Cote, Christopher K. Antibodies (Basel) Article Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human. MDPI 2023-05-08 /pmc/articles/PMC10204441/ /pubmed/37218899 http://dx.doi.org/10.3390/antib12020033 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Biryukov, Sergei S.
Wu, Hua
Dankmeyer, Jennifer L.
Rill, Nathaniel O.
Klimko, Christopher P.
Egland, Kristi A.
Shoe, Jennifer L.
Hunter, Melissa
Fetterer, David P.
Qiu, Ju
Davies, Michael L.
Bausch, Christoph L.
Sullivan, Eddie J.
Luke, Thomas
Cote, Christopher K.
Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title_full Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title_fullStr Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title_full_unstemmed Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title_short Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
title_sort polyclonal antibodies derived from transchromosomic bovines vaccinated with the recombinant f1-v vaccine increase bacterial opsonization in vitro and protect mice from pneumonic plague
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204441/
https://www.ncbi.nlm.nih.gov/pubmed/37218899
http://dx.doi.org/10.3390/antib12020033
work_keys_str_mv AT biryukovsergeis polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT wuhua polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT dankmeyerjenniferl polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT rillnathanielo polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT klimkochristopherp polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT eglandkristia polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT shoejenniferl polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT huntermelissa polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT fettererdavidp polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT qiuju polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT daviesmichaell polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT bauschchristophl polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT sullivaneddiej polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT lukethomas polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague
AT cotechristopherk polyclonalantibodiesderivedfromtranschromosomicbovinesvaccinatedwiththerecombinantf1vvaccineincreasebacterialopsonizationinvitroandprotectmicefrompneumonicplague